Page last updated: 2024-09-05

deferasirox and Allergic Bronchopulmonary Mycosis

deferasirox has been researched along with Allergic Bronchopulmonary Mycosis in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Albert, ND; Kontoyiannis, DP; Lewis, RE1
Edwards, JE; French, SW; Gebremariam, T; Ibrahim, AS; Spellberg, B1

Other Studies

2 other study(ies) available for deferasirox and Allergic Bronchopulmonary Mycosis

ArticleYear
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
    Antimicrobial agents and chemotherapy, 2014, Volume: 58, Issue:11

    Topics: Amphotericin B; Animals; Antifungal Agents; Area Under Curve; Aspergillosis; Aspergillus fumigatus; Benzoates; Caspofungin; Deferasirox; Disease Models, Animal; Drug Therapy, Combination; Echinocandins; Female; Invasive Pulmonary Aspergillosis; Lipopeptides; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mucormycosis; Neutropenia; Rhizopus; Treatment Outcome; Triazoles

2014
The iron chelator deferasirox enhances liposomal amphotericin B efficacy in treating murine invasive pulmonary aspergillosis.
    The Journal of antimicrobial chemotherapy, 2010, Volume: 65, Issue:2

    Topics: Amphotericin B; Animals; Antifungal Agents; Aspergillus fumigatus; Benzoates; Deferasirox; Drug Synergism; Drug Therapy, Combination; Humans; Invasive Pulmonary Aspergillosis; Male; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Survival Analysis; Treatment Outcome; Triazoles

2010
chemdatabank.com